Preserving Ocular Surface Health
Intraocular pressure (IOP) is a major risk factor in the onset of visual field loss due to glaucoma. The higher the IOP, the greater the likelihood of visual field loss and ocular nerve damage.1
TIMOPTIC®, when applied to the eye, acts to reduce both elevated and normal IOP.1
Unlike other treatments, TIMOPTIC® in OCUDOSE® is not just BAK-free — it’s a completely preservative-free glaucoma treatment that doesn’t compromise the ocular surface.2
- Studies have shown that a preservative-free timolol eye drop is less toxic for the ocular surface3
Preservative-free formulation minimizes inflammatory activation of
interleukin-1β (IL-1β).2
- IL-1β is a key regulator of ocular surface inflammation that can lead to clinical ocular surface alterations4
- Preserved therapy resulted in significantly greater increase in IL-1β concentration4
Repeated use of glaucoma medication with preservatives like BAK can have detrimental effects on the ocular tissue.5
- For glaucoma patients at risk for ocular surface damage, preservative-free medication may reduce side effects and increase medication tolerability
References: 1. Timoptic (timolol maleate ophthalmic solution) in Ocudose (dispenser) [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2009. 2. Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1β tear concentration in glaucomatod/us and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139:72-77. 3. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423. 4. Li DQ, Tseng SC. Three patterns of cytokine expression potentially involved in epithelial-fibroblast interactions of human ocular surface. J Cella Physiol. 1995;163:61-79. 5. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
